Avistone Biotechnology
Brand
Avistone operates two wholly-owned subsidiaries:
Beijing Pearl Biotechnology Co., Ltd. and
Beijing Avistone New Drug Technology Co.,Ltd.
2012年
Inception of Beijing Pearl Biotechnology Co., Ltd.
2018年
Inception of Beijing Avistone Biotechnology Co., Ltd.
Search More
About the Team
Team
Sharing the same dream and targets, a group of talented individuals came together. They helped and encouraged each other, overcoming all obstacles and challenges to forge a bright future for others.
Search More
-
Shi HepengFounder, Chairman and CEO of Avistone -
Zhang PeilongChief Technology Officer, Avistone -
David ChungChief Business Officer, Avistone -
Kevin Schaab, Ph.D.VP, Non-Clinical Development & CMC
Science & Innovation
products
Clinical study of MET exon 14 mutation and primary
MET amplification in non-small cell lung cancer:
News
2021-12-09On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") announced the closure of Series A funding, raising over $200 million.
2022-09-28Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.
2022-09-15On September 15, 2022, the finals for biomedical section in the 2022 Zhongguancun International Frontier Technology Innovation Competition was held in Zhongguancun Lif Sciences Park in Beijing's Changping District. Ten technology companies emerged from the rank and file and were named Top 10 finalists.
2022-03-15Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") recently announced closure of Series A funding, raising over $200 million.
Company Profile
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
京ICP备2020040683号-2